Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
- Registration Number
- NCT00312013
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 503
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Nadroparin Nadroparin Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.
- Primary Outcome Measures
Name Time Method Death due to all causes at study end (patients will be followed until at least Week 46 after randomization). AT least 46 weeks after randomization
- Secondary Outcome Measures
Name Time Method Time to tumor progression 46 weeks
Trial Locations
- Locations (1)
GSK Investigational Site
🇸🇮Ljubljana, Slovenia